Resveratrol, the powerful polyphenol from both red wine and red grape skin, is considered a
potential cancer preventive agent. In this study researchers exposed ER-alpha, ER-beta, and
MDA-MB-231 human breast cancers growing in nude mice to Resveratrol. Nude mice are commonly used
in cancer research because they lack a thymus gland, T-cells, and therefore immune function and it
is easy to insert a human cancer in them and the cancer flourishes in them. ER-alpha and ER-beta
are two estrogen receptor sites and it is thought by some experts that women with cancer that is
ER-alpha positive have a lower risk of relapse and better overall survival. MDA-MB-123
adenocarcinoma is a highly invasive and aggressive breast cancer cell-line. The Resveratrol causes
significantly lower tumor growth, decreased the ability of the cancers to create their own blood
supply (angiogenesis), and increased the rate of death of all 3 types of breast cancers. There was
also significantly reduced levels of VEGF (vascular endothelial growth factor) a factor needed for
the growth and metastasis of breast cancer. This study supports the potential use of Resveratrol as
a chemotherapeutic agent in breast cancer. The research was performed at the Division of Gynecologic
Oncology, Faculty of Health Sciences, University Hospital, Linkoping, Sweden and is published in the
January 2006 issue of Cancer Letters.
Commentary by Jerry Hickey, R.Ph.
At the start of this study the impact of the supplements Green Tea Extract and CLA were not
even thought of yet - studies show these both impact weight.
EGCG is the most important polyphenol in Green Tea
Increasing evidence points to EGCG having an ability to protect nerves, the nervous system and it
may especially protect motor neurons. Motor neurons are nerve cells of the brain and spinal cord
that control muscle and enable movement. In ALS (amyotrophic lateral sclerosis [sometimes called Lou
Gehrig's disease]) there is damage to motor neurons that rapidly worsens weakening muscles eventually
leading to death. The neuroprotective effects of EGCG have been demonstrated in Parkinson's disease,
Alzheimer's disease, and models of ischemic stroke, there has been no report on the effects of a
living model of ALS. In this study mice with damage to their SOD1 genes had a form of ALS that occurs
because SOD is not functioning to protect their brain. 3 groups of 11 mice were treated with
different concentrations of EGCG dissolved in their drink, or nothing added starting before they
displayed symptoms of ALS. The EGCG in concentrations over 2.9 mcg/g of body weight significantly
prolonged the time before symptoms occurred and significantly prolonged lifespan. This data suggests
that EGCG could be a potential therapeutic candidate for ALS as a disease-modifying agent. The study
was performed at the Department of Neurology, Institute of Biomedical Science, College of Medicine,
Hanyang University, Seoul, South Korea and is published early on line ahead of print in the December
12th, 2005 issue of Neuroscience Letters.
*These statements have not been evaluated by the Food and Drug Administration. These products are not intended to treat, diagnose, cure, or prevent any disease.
All customer information is kept confidential. We do not give, rent or sell our customer information. Customer information is kept for company records only.